The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
somatrogon-ghla · SOMATROGON 24 mg/1.2mL · Injection, Solution · Subcutaneous · Pfizer Laboratories Div Pfizer Inc
NDC 00069-0505-02 · 1 CARTRIDGE in 1 CARTON / 1.2 mL in 1 CARTRIDGE · BLA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | SOMATROGON 24 mg/1.2mL | Jul 15, 2026 | Sep 2, 2026 |
| Pfizer Laboratories Div Pfizer Inc | SOMATROGON 60 mg/1.2mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Ngenla — NDC 00069-0505-02," retrieved September 3, 2026, https://drugdashboards.com/drug/00069050502.
Free to cite with attribution — see how the data is put together.